TRIO-US AstraZeneca D910GC00001 “Matterhorn”
A Randomized, Double-blind, Placebo-controlled, Phase III Study
of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy
Followed by Adjuvant Durvalumab in Patients with Resectable
Gastric and Gastroesophageal Junction Cancer (GC/GEJC)
(MATTERHORN)
©2019 Fort Wayne Medical Oncology and Hematology. All Rights Reserved.